KR20180014768A - 소프트 콘택트렌즈가 착용된 드라이아이 환자의 눈에 점안되도록 이용되는 것을 특징으로 하는 드라이아이 치료제 - Google Patents

소프트 콘택트렌즈가 착용된 드라이아이 환자의 눈에 점안되도록 이용되는 것을 특징으로 하는 드라이아이 치료제 Download PDF

Info

Publication number
KR20180014768A
KR20180014768A KR1020177037651A KR20177037651A KR20180014768A KR 20180014768 A KR20180014768 A KR 20180014768A KR 1020177037651 A KR1020177037651 A KR 1020177037651A KR 20177037651 A KR20177037651 A KR 20177037651A KR 20180014768 A KR20180014768 A KR 20180014768A
Authority
KR
South Korea
Prior art keywords
contact lens
eye
soft contact
salt
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177037651A
Other languages
English (en)
Korean (ko)
Inventor
요시히로 오시타
히토시 나카자와
이사오 마츠오카
아즈카 가미무라
Original Assignee
산텐 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산텐 세이야꾸 가부시키가이샤 filed Critical 산텐 세이야꾸 가부시키가이샤
Publication of KR20180014768A publication Critical patent/KR20180014768A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177037651A 2015-06-05 2016-06-03 소프트 콘택트렌즈가 착용된 드라이아이 환자의 눈에 점안되도록 이용되는 것을 특징으로 하는 드라이아이 치료제 Ceased KR20180014768A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2015-114596 2015-06-05
JP2015114596 2015-06-05
PCT/JP2016/066590 WO2016195072A1 (ja) 2015-06-05 2016-06-03 ソフトコンタクトレンズが装用されたドライアイ患者の眼に点眼されるように用いられることを特徴とするドライアイ治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207018549A Division KR20200079572A (ko) 2015-06-05 2016-06-03 소프트 콘택트렌즈가 착용된 드라이아이 환자의 눈에 점안되도록 이용되는 것을 특징으로 하는 드라이아이 치료제

Publications (1)

Publication Number Publication Date
KR20180014768A true KR20180014768A (ko) 2018-02-09

Family

ID=57441364

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177037651A Ceased KR20180014768A (ko) 2015-06-05 2016-06-03 소프트 콘택트렌즈가 착용된 드라이아이 환자의 눈에 점안되도록 이용되는 것을 특징으로 하는 드라이아이 치료제
KR1020207018549A Ceased KR20200079572A (ko) 2015-06-05 2016-06-03 소프트 콘택트렌즈가 착용된 드라이아이 환자의 눈에 점안되도록 이용되는 것을 특징으로 하는 드라이아이 치료제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207018549A Ceased KR20200079572A (ko) 2015-06-05 2016-06-03 소프트 콘택트렌즈가 착용된 드라이아이 환자의 눈에 점안되도록 이용되는 것을 특징으로 하는 드라이아이 치료제

Country Status (11)

Country Link
US (3) US10729712B2 (enExample)
EP (1) EP3305301B1 (enExample)
JP (5) JP2017002035A (enExample)
KR (2) KR20180014768A (enExample)
CN (2) CN107635565A (enExample)
CA (1) CA2987882A1 (enExample)
ES (1) ES2999137T3 (enExample)
HK (1) HK1245651A1 (enExample)
RU (1) RU2742032C2 (enExample)
TW (1) TW201707710A (enExample)
WO (1) WO2016195072A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021261927A1 (ko) * 2020-06-23 2021-12-30 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
WO2021261930A1 (ko) * 2020-06-23 2021-12-30 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
KR20220092164A (ko) * 2020-12-24 2022-07-01 주식회사 종근당 디쿠아포솔 또는 이의 약제학적으로 허용가능한 염과 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119114152A (zh) * 2017-06-17 2024-12-13 株式会社Acenet 自由基产生催化剂、自由基的制造方法、氧化反应产物的制造方法、药剂和农畜产用药剂
CN108853016A (zh) * 2018-09-26 2018-11-23 广州大光制药有限公司 一种地夸磷索钠滴眼液及其制备方法
KR20240049646A (ko) * 2019-08-27 2024-04-16 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물
CN113712909A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种复方地夸磷索四钠滴眼液及其制备方法
WO2022113970A1 (ja) * 2020-11-30 2022-06-02 学校法人近畿大学 涙液層破壊時間短縮型ドライアイ治療剤および該治療剤を含む点眼剤
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
CN114187994A (zh) * 2021-12-06 2022-03-15 上海泽充生物技术有限公司 一种提示干眼症患者定期滴眼并记录的系统

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501605A (ja) * 1996-09-20 2001-02-06 ボシュ アンド ロム インコーポレイテッド コンタクトレンズの再湿潤および眼の乾燥の緩和のための方法および組成物
JP2011026303A (ja) * 2009-06-30 2011-02-10 Lion Corp 眼科用組成物及び白濁・沈殿抑制方法
JP2012149057A (ja) * 2010-12-28 2012-08-09 Santen Pharmaceut Co Ltd ジクアホソル含有点眼液およびその製造方法、不溶性析出物発生の抑制方法
JP2013227291A (ja) * 2012-03-26 2013-11-07 Santen Pharmaceut Co Ltd ジクアホソル含有点眼液
KR20140012061A (ko) * 2011-01-18 2014-01-29 센주 세이야꾸 가부시키가이샤 보존 효력을 갖는 브롬페낙 수성 액제 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029817A (en) * 1973-09-24 1977-06-14 Allergan Pharmaceuticals Soft contact lens preserving solutions
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US20040214754A1 (en) * 2001-10-03 2004-10-28 Ellis Edward J. Ophthalmic preparation containing glycomacropeptide
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
KR101690816B1 (ko) 2009-06-25 2016-12-28 라이온 가부시키가이샤 안과용 조성물 및 백탁·침전 억제 방법
EP3434257A1 (en) * 2010-07-29 2019-01-30 Allergan, Inc. Preservative free brimonidine and timolol solutions
CN103096929A (zh) * 2010-09-10 2013-05-08 参天制药株式会社 以组合p2y2受体激动剂和透明质酸或其盐为特征的干眼症治疗剂、干眼症的治疗方法、及干眼症治疗剂的应用
JP5686454B1 (ja) * 2013-12-12 2015-03-18 株式会社メニコン コンタクトレンズ装着用液剤およびそれを用いたコンタクトレンズの屈折率向上方法
SG11201705138QA (en) * 2014-12-25 2017-07-28 Santen Pharmaceutical Co Ltd Aqueous ophthalmic solution

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501605A (ja) * 1996-09-20 2001-02-06 ボシュ アンド ロム インコーポレイテッド コンタクトレンズの再湿潤および眼の乾燥の緩和のための方法および組成物
JP2011026303A (ja) * 2009-06-30 2011-02-10 Lion Corp 眼科用組成物及び白濁・沈殿抑制方法
JP2012149057A (ja) * 2010-12-28 2012-08-09 Santen Pharmaceut Co Ltd ジクアホソル含有点眼液およびその製造方法、不溶性析出物発生の抑制方法
KR20140012061A (ko) * 2011-01-18 2014-01-29 센주 세이야꾸 가부시키가이샤 보존 효력을 갖는 브롬페낙 수성 액제 조성물
JP2013227291A (ja) * 2012-03-26 2013-11-07 Santen Pharmaceut Co Ltd ジクアホソル含有点眼液

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021261927A1 (ko) * 2020-06-23 2021-12-30 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
WO2021261931A1 (ko) * 2020-06-23 2021-12-30 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
WO2021261930A1 (ko) * 2020-06-23 2021-12-30 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
KR20220092164A (ko) * 2020-12-24 2022-07-01 주식회사 종근당 디쿠아포솔 또는 이의 약제학적으로 허용가능한 염과 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물

Also Published As

Publication number Publication date
US10729712B2 (en) 2020-08-04
US20180147230A1 (en) 2018-05-31
EP3305301C0 (en) 2024-11-27
KR20200079572A (ko) 2020-07-03
JP2017002035A (ja) 2017-01-05
JP2025096568A (ja) 2025-06-26
US10918656B2 (en) 2021-02-16
RU2742032C2 (ru) 2021-02-01
US20200254000A1 (en) 2020-08-13
JP2024014996A (ja) 2024-02-01
RU2017145545A (ru) 2019-07-09
HK1245651A1 (en) 2018-08-31
WO2016195072A1 (ja) 2016-12-08
US20210128601A1 (en) 2021-05-06
RU2017145545A3 (enExample) 2019-11-21
EP3305301A1 (en) 2018-04-11
EP3305301B1 (en) 2024-11-27
TW201707710A (zh) 2017-03-01
EP3305301A4 (en) 2019-02-13
CN113143948A (zh) 2021-07-23
JP2021073289A (ja) 2021-05-13
CA2987882A1 (en) 2016-12-08
JP2022093383A (ja) 2022-06-23
CN107635565A (zh) 2018-01-26
ES2999137T3 (en) 2025-02-24

Similar Documents

Publication Publication Date Title
KR20180014768A (ko) 소프트 콘택트렌즈가 착용된 드라이아이 환자의 눈에 점안되도록 이용되는 것을 특징으로 하는 드라이아이 치료제
JP7472202B2 (ja) ジクアホソルおよびカチオン性ポリマーを含有する眼科用組成物
KR102330736B1 (ko) 수성 점안액
JP6966667B2 (ja) ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
KR102877318B1 (ko) 디쿠아포솔 또는 그 염, 비닐계 고분자 및 셀룰로오스계 고분자를 함유하는 안과용 조성물
JP6267003B2 (ja) ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
HK40051709A (en) Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens
JP7230169B2 (ja) ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
HK1246642A1 (en) Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens
JP7089131B1 (ja) 塩化ポリドロニウムを含有する水性点眼液
WO2022107791A1 (ja) ポリヘキサメチレンビグアナイドまたはその塩を含有する水性点眼液

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180509

Comment text: Request for Examination of Application

A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20180515

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180904

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190224

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180904

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190224

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20181204

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180725

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180509

Comment text: Amendment to Specification, etc.

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20190701

Patent event code: PE09021S02D

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20200330

Comment text: Final Notice of Reason for Refusal

Patent event code: PX06013S02I

Patent event date: 20190701

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190524

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190224

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181204

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180904

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180725

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180509

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200626

PJ0201 Trial against decision of rejection

Patent event date: 20200626

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20200330

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20190224

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20210722

Appeal identifier: 2020101001653

Request date: 20200626

J301 Trial decision

Free format text: TRIAL NUMBER: 2020101001653; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20200626

Effective date: 20210722

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20210722

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20200626

Decision date: 20210722

Appeal identifier: 2020101001653